Posts

Antheia gets conditional $80 million commitment to onshore drug ingredients

Antheia has received a conditional commitment for a direct, long-term loan of up to $80 million from the Department of War’s Office of Strategic Capital to help establish U.S. production of pharmaceutical ingredients. The proposed funding, alongside private capital, is intended to bring key starting materials and active pharmaceutical ingredients (APIs) used in generic medicines onshore. Antheia uses engineered yeast fermentation to make these ingredients. The loan has not closed and the money has not been disbursed. Antheia must meet financial, legal, technical, investment and due-diligence requirements first. The federal announcement does not specify a manufacturing site, production capacity or timeline. Trump separately mentioned a possible $100 million investment in a Winchester, Kentucky, facility, conditional on Republicans winning the midterms; public details do not establish that this pledge is part of the $80 million loan. Sources: Antheia Secures $80 Million Conditi...

Rapport’s bipolar trial clears a key hurdle, but the size of the benefit draws scrutiny

Lycia seeks $228 million IPO to advance experimental food-allergy drugs

EyePoint and Enlivex announce major workforce cuts

Lilly and Metis TechBio strike potential $1.1B AI drug-delivery deal

Gilead’s emvistegrast posts positive Phase 2 ulcerative colitis results

TriGemX Bio plans SPAC merger to fund migraine drug development

Veradermics reports another positive Phase 3 trial for oral minoxidil

Merck KGaA to acquire Silence Therapeutics for about $1.3 billion

AltruBio reports early ALTB-268 results in refractory ulcerative colitis

AstraZeneca previews four Phase III survival presentations at ESMO 2026

Disc Medicine’s bitopertin succeeds in Phase 3 after FDA rejection

Roche and Hansoh strike potential $15B-plus cancer-drug deal